Abbott Laboratories Acquires EXACT Sciences Transforming Cancer Screening Together

Highlights of the report

Abbott Laboratories agreed to acquire EXACT Sciences for $105 per common share, total equity value of approximately $21 billion and an estimated enterprise value of $23 billion. The price reflects a representing a 51% premium to Exact Sciences closing price of $69.68 on November 18, 2025.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

 Abbott is joining forces with Exact Sciences to strengthen its fight against cancer. Exact brings in powerful tools like Cologuard®, which helps detect colon cancer early, and Oncotype DX®, which guides treatment decisions for breast cancer and many more.

Abbott’s legal advisor is Wachtell, Lipton, Rosen & Katz. While its financial advisors is Morgan Stanley is serving as the exclusive financial advisor for Abbott and has provided fully committed debt financing.

Exact Sciences Corporation is a leading molecular diagnostics company pioneering advanced cancer detection and precision oncology solutions through its integrated portfolio of screening, diagnostic, and monitoring technologies.

Executive Summary………………….…………………………………………………………..3
• Deal Overview………………………….………………………………………………………….5
• Business Rationale………………………………………………………………………………..6
• Company Overview – EXACT Sciences Corp..….………….……………………….13
• Company Overview – Abbott Laboratories…….…..………….……………….…..25

This report was produced by a member company of the Crispidea. This report is for the use of intended recipients only and may not be reproduced (in whole or in part) or delivered or transmitted to any other person without our prior written consent. By accepting this report, the recipient agrees to be bound by the terms and limitations set out herein.

https://www.crispidea.com/report-category/sector-research-reports-industry/

Report details

Abbott Laboratories Acquires EXACT Sciences Transforming Cancer Screening Together

  • Pages
  • 50
  • Format
  • PDF
  • Language
  • English
  • Released
  • November 24, 2025
  • Last Updated
  • November 24, 2025

Price

$416.00

Company Reports

Nike

Nike Inc. (NKE) (Q2FY26) – Innovation thrives amid challenges ahead

NKE’s Greater China business remains a major weakness and continues to drag on overall performance. In Q2FY6, revenue fell 16%, with NIKE Direct declining 18%, digital down 36%, stores down 5%, and wholesale down 15%, while EBIT plunged 49% Y/Y.
$280 Purchase
rapid7

Rapid7, Inc. (RPD) (Q3FY25) – Unified security operations platform positioning

Rapid7 is undertaking meaningful organizational changes aimed at improving sales execution and forecasting reliability.
$240 Purchase
Air Products

Air Products and Chemicals, Inc (APD.N) (Q4FY25) – Discipline restored

APD industrial gas industry is a stable, contract-driven sector characterized by long-term customer relationships, high switching costs, and mission-critical end-use applications.
$252 Purchase
Fair Isaac Corporation

Fair Isaac Corporation (FICO) (Q4FY25)Estimates skew favorably on pricing

FICO Score 10T further strengthens the competitive moat, with management highlighting that the model identifies 18% more defaulters within key score bands and enables 5% higher originations without incremental risk.
$248 Purchase
AbbVie

AbbVie Inc (ABBV) (Q3FY25) -Skyrizi and Rinvoq anchor growth for Abbvie

AbbVie’s capital allocation demonstrates discipline through the announced 5.5% dividend increase to $1.73 per  share beginning February 2026.
$256 Purchase
Eaton Corporation

Eaton Corporation plc. (ETN) (Q3FY25) – Electrification with visibility

Eaton’s operating margins have structurally reset higher, with EBIT margins rising from low-teens historically to high-teens around ~20% levels in recent years.
$264 Purchase

Sector Reports

The Magnificent 7 Stocks FY25 Performance

The Magnificent 7 Stocks FY25 Performance: Leadership Narrowed, Returns Followed

The tech-heavy World Infotech index dropped 32.18%, while the Nasdaq Composite fell 29.57% in FY25. Furthermore, all Magnificent 7 companies finely performed the broader indices except for Tesla and Microsoft.
$1976 Purchase

Electric Vehicles Industry Report 2025 – Powering the Next Era of Global Mobility

The global electric vehicle (EV) market is entering a decisive growth phase, transitioning from early adoption to mass-market penetration.
$2952 Purchase

AI in Cyber Security – 2025 – From Reactive Security to Predictive Protection

Over the next few years, AI will move from being a differentiator to a necessity, defining how effectively organizations can protect digital assets, ensure regulatory compliance, and maintain trust in an increasingly interconnected and threat-intensive digital economy.  
$2424 Purchase

E-Commerce Industry Report – 2025 After the Boom, E-Commerce Enters Its Disciplined Decade

The global e-commerce industry in 2025 entered a more mature and competitive phase, shaped by slowing growth in developed markets, rising customer acquisition costs, and rapidly evolving consumer expectations.
$2000 Purchase

Pharmaceuticals Industry Report – 2025 Transforming Molecules into Medicines

The global pharmaceutical industry is entering a pivotal period marked by rapid scientific advancement, evolving healthcare demands, and substantial market transformation. Innovation remains the core engine of growth, particularly in biologics, biosimilars, oncology, immunology, and metabolic disorders.
$2000 Purchase

AI in Insurance – 2025 Personalized Policies Powered by AI

Artificial Intelligence (AI) is reshaping the global insurance industry by transforming how products are designed, risks are assessed, and claims are managed. Insurers are moving beyond traditional actuarial models and manual workflows toward data-driven decision engines that leverage machine learning, natural language processing, and predictive analytics.
$400 Purchase